N@N

Spectral Molecular Imaging Releases Investor Information Briefing on Companya?s Development of Advanced Devices for Cancer Dete

^{Published on 2010-06-11 06:35:40 - Market Wire}
 

BEVERLY HILLS, Calif.--([ BUSINESS WIRE ])--Spectral Molecular Imaging, a wholly-owned subsidiary of Cascade Technologies, Inc. (OTCBB: CSDT), has announced the availability of a new Investor Information Brief outlining the Companya™s proprietary technology and its strategy to develop a line of optical imaging devices for earlier detection of cancer and other major disease.

"Our goal is for MelaSpect(tm) and our other devices to become part of the standard of care in cancer detection, significantly improving patient outcomes while lowering healthcare costs."

SMI is applying proprietary high-resolution optical imaging technology - originally developed for use in satellite reconnaissance - to develop a range of imaging devices to detect major disease and assess the health of tissues during and after surgery.

The Companya™s hyperspectral imaging technology is designed to enable the live, real-time identification and analysis of molecular, cellular and tissue features indicating cancer and other serious conditions, significantly earlier and more accurately than currently possible.

Among the Companya™s products in development is MelaSpect(tm), an imaging device designed to provide early and reliable detection of skin cancer, including melanoma, the deadliest type of skin cancer.

Cancer of the skin is the most common type of cancer in the U.S., with more than one million Americans diagnosed every year. Melanoma is responsible for approximately 75% of all deaths from skin cancer; it is also the fastest growing cancer in the U.S. and worldwide, increasing in incidence approximately 20-fold since 1935. Early detection remains the only effective means of fighting melanoma, but at present dermatologists rely primarily on visual examinations of patients to identify suspicious skin tissues, an approach that carries a significant potential for ambiguous and inaccurate diagnosis.

SMI is also applying its spectral imaging technology to develop products to monitor tissue health during both minimally invasive and major procedures, including open-heart surgery.

aSMIa™s proprietary technology addresses medical needs that are not only vitally important today, but will become more significant within the next decade,a said Daniel L. Farkas, Ph.D., Chairman of SMI. aOur goal is for MelaSpect(tm) and our other devices to become part of the standard of care in cancer detection, significantly improving patient outcomes while lowering healthcare costs.a

Investors interested in learning more about SMIa™s technology and product development can view or download the Investor Information Brief at the companya™s website, [ http://www.spectralmi.com ].

About Spectral Molecular Imaging

Spectral Molecular Imaging, Inc., a wholly-owned subsidiary of Cascade Technologies, Inc., is a development-stage, medical imaging device company. Application of SMIa™s proprietary spectral-optical imaging technologya"originally developed for satellite reconnaissancea"is expected to advance the diagnoses of cancer and precancerous conditions. SMI is developing non-invasive imaging systems using its patented technology for improved clinical diagnostics, primarily in the field of cancer pathology. SMIa™s devices utilize high-resolution imaging, identification, and analysis of certain molecular, cellular, and tissue features via patented spectral-imaging approaches. We also intend to provide services related to our primary products, including software modules and maintenance services, and to develop optical diagnostic products that operate in conjunction with surgical and/or evaluation procedures in real time. Our technology is expected to enable early detection and more reliable diagnosis of various diseases, including skin cancers such as melanoma, Barretta™s esophagus (a condition caused by chronic acid reflux that can lead to esophageal cancer) and lung cancer. The development of this technology is expected to significantly improve long-term patient outcomes while substantially reducing overall costs for the healthcare system. For more information, please visit [ http://www.spectralmi.com ].

Forward-Looking Statements

The content of this news announcement contains or may contain certain "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties, including those detailed in filings made by Cascade Technologies, Inc., SMI's parent, with the Securities and Exchange Commission. Forward-looking statements may include, without limitation, statements regarding SMI's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects", "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of SMI's management; however, actual results, including, without limitation, actual sales and other financial results, may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve risks and uncertainties that are subject to change based on various factors, many of which are beyond SMI's control.